FRETS-VWF73 rather than CBA assay reflects ADAMTS13 proteolytic activity in acquired thrombotic thrombocytopenic purpura patients

Thrombosis and Haemostasis

Volumn 112, Issue 2, 2014, Pages 297-303

  Mancini, Ilaria ^a   Valsecchi, Carla ^a   Lotta, Luca Andrea ^a   Deforche, Louis ^b   Pontiggia, Silvia ^a   Bajetta, Mariateresa ^a   Palla, Roberta ^a   Vanhoorelbeke, Karen ^b   Peyvandi, Flora ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

ADAMTS13 activity assay; Autoantibodies; Flow assay; TTP; Von Willebrand factor

Indexed keywords

AUTOANTIBODY; BILIRUBIN; IMMUNOGLOBULIN G; PROTEIN INHIBITOR; UREA; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN; COLLAGEN; PROTEIN BINDING; VON WILLEBRAND FACTOR;

ARTICLE; COLLAGEN BINDING ACTIVITY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FRETS VWF73 ASSAY; HUMAN; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; THROMBOTIC THROMBOCYTOPENIC PURPURA; WESTERN BLOTTING; BLOOD; CHEMISTRY; COMPARATIVE STUDY; DEFICIENCY; ENZYMOLOGY; FLUORESCENCE RESONANCE ENERGY TRANSFER; METABOLISM; PREDICTIVE VALUE; PROTEIN DENATURATION; PURPURA, THROMBOTIC THROMBOCYTOPENIC; REGISTER; REPRODUCIBILITY;

ADAM PROTEINS; COLLAGEN; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMANS; PREDICTIVE VALUE OF TESTS; PROTEIN BINDING; PROTEIN DENATURATION; PROTEOLYSIS; PURPURA, THROMBOTIC THROMBOCYTOPENIC; REGISTRIES; REPRODUCIBILITY OF RESULTS; UREA; VON WILLEBRAND FACTOR;

EID: 84905176550     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-08-0688     Document Type: Article

References (19)

1. Moake JL, Rudy CK, Troll JH, et al. Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982; 307: 1432-1435.
2. Sadler JE. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood 2008; 112: 11-18.
3. Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339: 1578-1584.
4. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 1585-1594.
5. Peyvandi F, Palla R, Lotta LA, et al. ADAMTS-13 assays in thrombotic thrombocytopenic purpura. J Thromb Haemost 2010; 8: 631-640.
6. Mannucci PM, Franchini M. Advantages and limits of ADAMTS13 testing in the prognostic assessment of thrombotic thrombocytopenic purpura. Presse Med 2012; 41: e157-162.
7. Kremer Hovinga JA, Vesely SK, Terrell DR, et al. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 2010; 115: 1500-1511; quiz 1662.
8. Gerritsen HE, Turecek PL, Schwarz HP, et al. Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP). Thromb Haemost 1999; 82: 1386-1389.
9. Kokame K, Nobe Y, Kokubo Y, et al. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005; 129: 93-100.
10. Palla R, Valsecchi C, Bajetta M, et al. Evaluation of assay methods to measure plasma ADAMTS13 activity in thrombotic microangiopathies. Thromb Haemost 2011; 105: 381-385.
11. Peyvandi F, Lavoretano S, Palla R, et al. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica 2008; 93: 232-239.
12. Lotta LA, Mariani M, Consonni D, et al. Different clinical severity of first episodes and recurrences of thrombotic thrombocytopenic purpura. Br J Haematol 2010; 151: 488-494.
13. Meyer SC, Sulzer I, Lammle B, et al. Hyperbilirubinemia interferes with ADAMTS-13 activity measurement by FRETS-VWF73 assay: diagnostic relevance in patients suffering from acute thrombotic microangiopathies. J Thromb Haemost 2007; 5: 866-867.
14. Tripodi A, Chantarangkul V, Bohm M, et al. Measurement of von Willebrand factor cleaving protease (ADAMTS-13): results of an international collaborative study involving 11 methods testing the same set of coded plasmas. J Thromb Haemost 2004; 2: 1601-1609.
15. De Ceunynck K, Rocha S, Feys HB, et al. Local elongation of endothelial cell-anchored von Willebrand factor strings precedes ADAMTS13 protein-mediated proteolysis. J Biol Chem 2011; 286: 36361-36367.
16. Bettoni G, Palla R, Valsecchi C, et al. ADAMTS-13 activity and autoantibodies classes and subclasses as prognostic predictors in acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 2012; 10: 1556-1565.
17. Lotta LA, Lombardi R, Mariani M, et al. Platelet reactive conformation and multimeric pattern of von Willebrand factor in acquired thrombotic thrombocytopenic purpura during acute disease and remission. J Thromb Haemost 2011; 9: 1744-1751.
18. Mackie I, Langley K, Chitolie A, et al. Discrepancies between ADAMTS13 activity assays in patients with thrombotic microangiopathies. Thromb Haemost 2013; 109: 488-496.
19. Froehlich-Zahnd R, George JN, Vesely SK, et al. Evidence for a role of antiADAMTS13 autoantibodies despite normal ADAMTS13 activity in recurrent thrombotic thrombocytopenic purpura. Haematologica 2012; 97: 297-303.